Provided by Tiger Fintech (Singapore) Pte. Ltd.

Denali Therapeutics Inc.

14.40
+1.259.51%
Volume:891.71K
Turnover:12.65M
Market Cap:2.09B
PE:-5.60
High:14.56
Open:13.41
Low:13.41
Close:13.15
Loading ...

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

GlobeNewswire
·
30 Jan

Denali Gains 26.6% in a Year: How Should You Play the Stock?

Zacks
·
21 Jan

Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential

Insider Monkey
·
18 Jan

BTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)

TIPRANKS
·
16 Jan

BRIEF-Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities

Reuters
·
13 Jan

Denali Therapeutics Inc: Anticipates Its Cash Runway Will Extend Into 2028

THOMSON REUTERS
·
13 Jan

Denali Therapeutics Inc: Preparing for Commercial Launch of Tividenofusp Alfa for Hunter Syndrome in Late 2025 or Early 2026

THOMSON REUTERS
·
13 Jan

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

GlobeNewswire
·
13 Jan

DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation

Zacks
·
10 Jan

Denali Gets FDA Breakthrough Therapy Designation for Hunter Syndrome Treatment

MT Newswires Live
·
08 Jan

BRIEF-Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted To Tividenofusp Alfa For The Treatment Of Hunter Syndrome (MPS II)

Reuters
·
08 Jan

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (Mps Ii)

THOMSON REUTERS
·
08 Jan

Denali Therapeutics Inc - Expects to Submit Bla for Tividenofusp Alfa in Early 2025

THOMSON REUTERS
·
08 Jan

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

GlobeNewswire
·
08 Jan

Denali Therapeutics price target lowered to $32 from $35 at BTIG

TipRanks
·
08 Jan

Denali's ALS Study Fails to Meet Primary and Secondary Endpoints

Zacks
·
08 Jan

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected

Benzinga
·
08 Jan

Denali recent pullback a buying opportunity, says Jefferies

TIPRANKS
·
07 Jan

Baird Initiates Denali Therapeutics at Outperform With $31 Price Target

MT Newswires Live
·
07 Jan

BUZZ-Denali Therapeutics falls after ALS drug fails in mid-to-late stage trial

Reuters
·
07 Jan